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Abstract 
Background 
The Harmonising Outcomes Measures for Eczema (HOME) initiative has identified QoL as a core 
outcome domain to be evaluated in every eczema trial. It is unclear which of the existing QoL 
instruments is most appropriate for this domain. Thus, the aim of this review was to systematically 
assess the measurement properties of existing measurement instruments developed and/or 
validated for the measurement of QoL in adult eczema. 
Methods 
We conducted a systematic literature search in PubMed and Embase identifying studies on 
measurement properties of adult eczema QoL instruments. For all eligible studies, we assessed the 
adequacy of the measurement properties and the methodological quality with the COnsensus-based 
Standards for the selection of health status Measurement INstruments (COSMIN) checklist. A best 
evidence synthesis summarizing findings from different studies was the basis to assign four degrees 
of recommendation (A-D). 
Results 
15 articles reporting on 17 instruments were included. No instrument fulfilled the criteria for 
category A. Six instruments were placed in category B, meaning that they have the potential to be 
recommended depending on the results of further validation studies. Three instruments had poor 
adequacy in at least one required adequacy criterion and were therefore put in category C. The 
remaining eight instruments were minimally validated and were thus placed in category D.  
Conclusions 
Currently, no QoL instrument can be recommended for use in adult eczema. The Quality of Life Index 
for Atopic Dermatitis (QoLIAD) and the Dermatology Life Quality Index (DLQI) are recommended for 
further validation research. 
Key words 
Core outcome set; eczema; HOME initiative; measurement properties; quality of life 
Abbreviations 
COS: Core outcome set; COSMIN: COnsensus-based Standards for the selection of health 
Measurement Instruments; DIF: Differential item functioning; HOME: Harmonising Outcome 
Measures in Eczema; HrQoL: health-related quality of life; ICC: Intraclass Correlation Coefficient; IRT: 
Item response theory; MIC: Minimal important change; MID: Minimal important difference; 
OMERACT: Outcome Measures in Rheumatology; PRISMA: Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses; QoL: quality of life 
Word count body text: 3,653 
Manuscript table count: 7 
Manuscript figure count: 1 
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Introduction 
Eczema (synonymous with atopic eczema, atopic dermatitis) is a common, chronic, relapsing skin 
disease that affects both children and adults. Recent studies suggest that eczema prevalence rates in 
adults are in excess of 10% (1, 2). There are numerous treatments for eczema, many of which have 
been studied in randomized controlled trials. However, the lack of standardization of eczema 
outcome measurement instruments in clinical trials currently limits the possibility to compare and 
synthesize results in order to determine the best treatments, hampering evidence-based decision 
making and rendering the generation of treatment recommendations difficult. 
Therefore, the Harmonising Outcome Measures in Eczema (HOME) initiative 
(www.homeforeczema.org) set out to define a core outcome set (COS) to be applied in all future 
eczema trials. A COS is an agreed minimum set of outcomes that should be measured and reported 
in all clinical trials of a specific disease or trial population (3). Clinical signs, symptoms, long-term 
control of flares and quality of life have been identified as the core outcome domains by the HOME 
initiative (4-6).  
In accordance with the HOME roadmap (7), we set out to perform a systematic review of the 
measurement properties of all instruments that were developed and validated to measure QoL in 
eczema patients.  
Methods 
Protocol and registration 
This systematic review was developed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (8). A study protocol was published 
beforehand (9) and has also been registered in the International Prospective Register of Systematic 
Reviews (PROSPERO): CRD42015017138. 
Literature search 
On 9 January 2015, we performed a systematic literature search in PubMed and EMBASE, as 
described in detail in the previously published protocol (9). 
It was supplemented by hand searching of reference lists of included studies and key articles on this 
topic. We also searched the PROQOLID database (http://www.proqolid.org).  
Eligible studies 
The eligibility criteria laid out in the protocol were applied (9). In accordance with a consensus-based 
decision of the HOME initiative (10), only disease- or dermatology-specific, and not generic QoL 
measurement instruments, were eligible.  
Assessment of the methodological quality of included studies 
The COnsensus-based standards for the selection of health Measurement Instruments (COSMIN) 
checklist was used to evaluate the methodological quality of the included studies (11-14).  
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Assessment of measurement properties and further characteristics of QoL 
instruments 
We assessed all measurement properties from the COSMIN checklist in this review, with the 
exception of criterion validity since no gold standard exists for QoL. Interpretability and feasibility 
data were collected where available. With the exception of content comparison and instrument 
characteristics, we regarded different language versions of the same questionnaire separately 
because we consider these to be distinct instruments. Our main reason for this approach was the fact 
that it cannot be assumed that different language versions of measurement instruments show the 
same measurement properties. Strictly speaking, it is the measurements that are valid, reliable and 
responsive and not the instruments per se. 
Content comparison 
We compared the content of each instrument at content domain level. In QoL questionnaires, 
subsets of items belonging together based on their content are often referred to as content domains. 
The original development paper for each instrument was consulted to obtain this information. We 
largely adopted the domains mentioned therein. 
Adequacy of the measurement properties 
The predefined criteria for rating the adequacy of measurement properties recommended by the 
COSMIN group were used in a slightly modified version (15) (Table 1). Hypothesis testing was split 
into the aspects convergent/divergent (defined as the correlation between instruments measuring 
similar/different constructs (16)) and discriminative validity (defined as the ability of a measurement 
instrument to distinguish between different subgroups of patients (16)) throughout the review. 
Findings from both aspects were integrated into an overall rating in the end (see also ‘Differences 
between protocol and review’). Where studies applied item response theory (IRT) methods in the 
evaluation of measurement properties, rather than in the development of measurement 
instruments, we were able to evaluate the adequacy and methodological quality of internal 
consistency, construct validity, structural validity, and cross-cultural validity. 
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Table 1: Adequacy criteria for measurement properties adapted from (15) and (17) 
Property  Rating Adequacy criteria 
Reliability   
Internal consistency 
(CTT methods 
applied) 
+ 
? 
- 
Cronbach's alpha(s) ≥ 0.70 
Cronbach’s alpha not determined 
Cronbach's alpha(s) < 0.70 
Internal consistency 
(IRT methods applied) 
+ 
? 
- 
Person Separation Index ≥ 0.70 
Person Separation Index not determined 
Person Separation Index < 0.70 
Measurement error + 
? 
- 
MIC > SDC OR MIC outside the LoA 
MIC not defined 
MIC <= SDC OR MIC equals or inside LoA 
Reliability + 
? 
- 
ICC/weighted Kappa >=0.70, OR Pearson’s r >= 0.80 
Neither ICC/weighted Kappa, nor Pearson’s r determined 
ICC/weighted Kappa < 0.70 OR Pearson’s r < 0.80 
Validity   
Content validity + 
 
 
 
? 
- 
All items are considered to be relevant for the construct to 
be measured, for the target population, and for the 
purpose of the measurement AND the questionnaire is 
considered to be comprehensive  
Not enough information available  
Not all items are considered to be relevant for the 
construct to be measured, for the target population, and 
for the purpose of the measurement OR the questionnaire 
is considered not to be comprehensive 
Construct validity   
Structural validity 
(CTT methods 
applied) 
+ 
? 
- 
Factors should explain at least 50% of the variance 
Explained variance not mentioned 
Factors explain < 50% of the variance 
Structural validity (IRT 
methods applied) 
+ 
 
 
 
 
 
? 
- 
Residual correlations among the items after controlling for 
the dominant factor < 0.20 OR Q3's < 0.37, item scalability 
>0.30, IRT model fit: G2 >0.01, no DIF for important subject 
characteristics (such as age, gender, education): 
McFadden's R2 < 0.02, OR no non-uniform DIF 
Important statistics not reported 
Residual correlations among the items after controlling for 
the dominant factor ≥ 0.20 OR Q3's ≥ 0.37, item scalability 
≤0.30, IRT model fit: G2 ≤0.01, important DIF for important 
subject characteristics (such as age, gender, education): 
McFadden's R2 ≥0.02, OR non-uniform DIF 
Hypothesis testing 
(convergent/divergent 
validity) 
+ 
 
 
 
? 
- 
Correlations with instruments measuring the same 
construct >=0.50 OR at least 75% of the results are in 
accordance with the hypotheses AND correlation with 
related constructs is higher than with unrelated constructs 
Solely correlations determined with unrelated constructs 
Correlations with instruments measuring the same 
construct < 0.50 OR < 75% of the results are in accordance 
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with the hypotheses OR correlation with related constructs 
is lower than with unrelated constructs 
Hypothesis testing 
(discriminative 
validity) 
+ 
 
 
? 
- 
Differences in scores on the measurement instrument for 
all evaluated patient subgroups are statistically significant 
OR ≥75% of results in accordance with hypotheses 
Some differences statistically significant, others not 
Differences in scores on the measurement instrument for 
all evaluated patient subgroups are not statistically 
significant OR <75% of results in accordance with 
hypotheses 
Cross-cultural validity + 
 
? 
 
- 
No differences in factor structure OR no important DIF 
between language versions 
Multiple group factor analysis not applied AND DIF not 
assessed 
Differences in factor structure OR important DIF between 
language versions 
Responsiveness   
Responsiveness + 
 
 
 
 
? 
- 
Correlation with changes on instruments measuring the 
same construct ≥ 0.50 OR at least 75% of the results are in 
accordance with the hypotheses OR AUC ≥ 0.70 AND 
correlations with changes in related constructs are higher 
than with unrelated constructs 
Solely correlations determined with unrelated constructs 
Correlations with changes on instruments measuring the 
same construct < 0.50 OR < 75% of the results are in 
accordance with the hypotheses OR AUC < 0.70 OR 
correlations with changes in related constructs are lower 
than with unrelated constructs 
  Abbreviations: DIF = Differential item functioning;  ICC = Intraclass correlation coefficient; IRT = Item response theory; LoA = Limits of 
agreement; MIC = Minimal important change; SDC = Smallest detectable change. 
+ positive rating, ? indeterminate rating, - negative rating 
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Best evidence synthesis 
Where an instrument was evaluated in multiple studies, the findings were synthesized provided the 
characteristics of the included studies were sufficiently similar and the methodological quality of the 
included studies was sufficient (18). The criteria for best evidence synthesis are outlined in Table 2. 
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Table 2: Levels of evidence for the overall adequacy of a measurement property, adapted from (19) 
Level Rating Criteria 
Strong +++, ? (strong) or --- Consistent findings in 
multiple studies of good 
methodological quality OR in 
one study of excellent 
methodological quality 
Moderate ++, ? (moderate) or -- Consistent findings in 
multiple studies of fair 
methodological quality OR in 
one study of good 
methodological quality 
Limited +, ? (limited) or - One study of fair 
methodological quality 
Conflicting +/- Conflicting findings 
Unknown  Weak Only studies of poor 
methodological quality  
+ positive rating, ? indeterminate rating, - negative rating 
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Generating recommendations for the use of QoL measurement instruments 
for eczema 
For each reviewed instrument, a standardized recommendation for usage or required future 
validation work was made depending on the adequacy of the instrument and the methodological 
quality of the included studies.  
Four categories of recommendation were made (9): 
A. QoL measurement instrument meets all requirements and is recommended for use. 
B. QoL measure meets two or more adequacy items, but performance in all other required 
adequacy items is unclear, so that the outcome measure has the potential to be 
recommended in the future depending on the results of further validation studies. 
C. QoL measure has low adequacy in at least one required adequacy criterion (≥1 rating of 
‘minus’) and therefore is not recommended to be used any more. 
D. QoL measure has (almost) not been validated. Its performance in all or most relevant 
adequacy items is unclear so that it is not recommended to be used until further validation 
studies clarify its adequacy. 
Finally, we aimed to identify one most appropriate (currently available) instrument to assess QoL in 
adults with eczema. 
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Differences between protocol and review 
In this manuscript, we specified that generic instruments are not eligible for our review. Unlike what 
was planned in the original protocol (9), we did not perform a content comparison at item level 
because the resulting comparison table would have been too large and thus not informative. Instead, 
we compared the content of the different QoL instruments at content domain level. 
For reasons of clarity, we decided to use the term “adequacy of the measurement properties” 
instead of “quality of the measurement properties”. For studies applying IRT methods, only internal 
consistency, construct validity, structural, and cross-cultural validity were evaluated, if applicable. In 
addition, as the review was conducted it was clear that some minor alterations were required to the 
adequacy criteria presented in table 3 of the protocol and table 1 of this review, respectively: 
• For internal consistency, the indeterminate rating (‘?’) was changed from “Dimensionality 
not known OR Cronbach’s alpha not determined” to “Cronbach’s alpha not determined” in 
order to avoid redundancy between the adequacy criteria and the COSMIN criteria for 
methodological quality. Adequacy criteria for IRT methods were added. 
• Although the adequacy criteria for content validity refer to a questionnaire’s target 
population (which may be other than eczema), we applied the same inclusion criteria for 
content validity studies like for the other measurement properties, i.e. at least 50% eczema 
patients in the sample or subgroup analysis for eczema patients presented, because we were 
interested in the instruments’ content validity in eczema patients. 
• The IRT criteria for structural validity were amended with information on differential item 
functioning (DIF) (20). A positive rating can now also be obtained if a study shows that there 
is no non-uniform DIF. Occurrence of non-uniform DIF results in a negative rating according 
to the new criteria. 
• The criteria suggested by Terwee et al. for hypothesis testing were only applied to 
convergent and divergent validity. Self-developed criteria for discriminative validity, which is 
another aspect of hypothesis testing, were added. The adequacy criteria for interpretability 
were omitted since interpretability is not considered to be a formal measurement property 
by the COSMIN initiative (12). 
The best evidence synthesis ratings were complemented by an indeterminate rating for strong, 
moderate and limited levels of evidence each. This was done for scenarios where a QoL instrument 
would obtain an indeterminate rating for a certain measurement property. An indeterminate rating 
was assigned where no clear evidence was available for either a positive or negative rating. 
In order to obtain an overall rating for hypothesis testing, findings from best evidence synthesis for 
convergent/divergent and discriminative validity were synthesized according to the following criteria: 
in case of conflicting ratings, the worse rating determined the overall rating for hypothesis testing; if 
either convergent/divergent or discriminative validity obtained an indeterminate rating, the rating 
for the other aspect of hypothesis testing determined the overall rating for hypothesis testing.  
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Results 
In total, we found 16 eligible articles (21-36) (Figure 1). Of these, we were able to obtain 15 full text 
papers. One manuscript pertaining to the Ukrainian versions of the Dermatology Life Quality Index 
(DLQI) and the Skindex-16 could not be procured and was thus excluded (25). 
Most of the included studies reported on the DLQI (n=6) (23, 24, 28-30, 35) and the Quality of Life 
Index for Atopic Dermatitis (QoLIAD, n=3) (31, 34, 36). Two studies presented information on the 
Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH) (32, 33). 
Skindex-29 was evaluated in two studies (22, 26). One study each was available for the Freiburg Life 
Quality Assessment core module (FLQA-c) (21), the Freiburg Life Quality Assessment for Dermatoses 
(FLQA-d) (23) and the Impact of Chronic Skin Disease on Daily Life (ISDL) (27). An overview of the 
content of these different instruments is shown in table 3. Symptoms and emotions are captured by 
six out of seven questionnaires whereas all other content domains are included in a lower number of 
instruments. Four instruments (DIELH, DLQI, FLQA-c and FLQA-d) share the most content domains 
whereas the QoLIAD does not have any content domains in common with the other QoL instruments. 
Other characteristics of the included instruments are shown in table 4. The number of items ranges 
from 10 to 54. Almost all instruments use a 4- or 5-point Likert scale. Only the ISDL applies a visual 
analogue scale (VAS) in addition, whereas the QoLIAD has a dichotomous response format. 
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Table 3: Comparison of the content of the different QoL instruments on domain level. 
Domain DIELH DLQI FLQA-c FLQA-d ISDL* QoLIAD 
Skindex-
29† 
Symptoms X X X X X  X 
Emotions X X X X X  X 
Activities of daily living X X X X X   
Leisure X X      
Work/study X X      
Social life X X X X X   
Treatment X X X X    
Functioning       X 
Satisfaction   X X    
Stigmatization     X   
Illness cognitions     X   
Need for mental and 
emotional stimulation 
     X  
Need for physical and 
emotional stability 
     X  
Need for security      X  
Need to share and belong      X  
Esteem needs      X  
Need for personal 
development and fulfillment 
     X  
*The ISDL distinguishes several higher level domains that contain a number of subordinate domains each. The subordinate domains were 
used for this content comparison. The exact domains are (subordinate domains in brackets): physical functioning (skin status; physical 
symptoms of itch, pain and fatigue; scratch response), psychological functioning (anxiety; negative mood; positive mood), stressors 
(disease impact on daily life; stigmatization), illness cognitions (helplessness; acceptance; perceived benefits), social support (perceived 
support; social network). 
†Content comparison of Skindex-29 is based on dimensions empirically derived from factor analysis and not on content-related domains. 
Abbreviations: DIELH = Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen; DLQI = Dermatology Life Quality 
Index; FLQA-c = Freiburg Life Quality Assessment core module; FLQA-d = Freiburg Life Quality Assessment for Dermatoses; ISDL = Impact of 
Chronic Skin Disease on Daily Life; QoLIAD = Quality of Life Index for Atopic Dermatitis 
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Table 4: Characteristics of the different instruments. 
Characteristic DIELH DLQI FLQA-c FLQA-d ISDL QoLIAD Skindex-29 
Target 
population 
Patients with any 
dermatological 
condition 
Patients with skin 
disease 
Patients with skin 
disease 
Patients with 
chronic 
inflammatory 
skin disease 
Patients with chronic 
skin disease 
Eczema patients 
Patients with 
skin disease 
Number of items 36 10 28 54 32 25 29 
Number of 
subscales 
7 6 6 6 5 None 3 
Number/type of 
response 
categories 
5-point Likert 
scale (and ‘not 
applicable’) 
4-point Likert scale 5-point Likert scale ND 
10-cm-VAS for 
physical symptoms; 5-
point Likert scale for 
positive and negative 
mood; 4-point Likert 
scale for all other 
scales 
Dichotomous 
(true/not true) 
5-point Likert 
scale 
Scoring 
algorithm 
Calculation of a 
sum score, range 
0-180 
Calculation of a sum 
score, range 0-30 
Calculation of a 
scale score by 
averaging the 
answers within a 
scale, range 1-5; 
no total score 
ND 
Calculation of 
subscale scores by 
summing up the 
subscales’ items 
scores 
Calculation of a sum 
score, range 0-25 
Calculation of a 
scale score by 
averaging 
responses to 
items in a given 
scale 
Recall period in 
the items 
ND 1 week 1 week ND ND ND ND 
Administration 
costs 
ND 
No charge for 
unfunded studies; 
$9.50 per patient for 
pharmaceutical 
companies (37) 
ND ND ND 
No charge for non-
commercial studies; 
Administration fee of 
£100 for commercial 
studies (38) 
ND 
Available 
translations 
German More than 90 (37) German German Dutch 
Dutch, English (UK), 
English (US), French, 
German, Italian, 
Japanese, Spanish (39) 
16 language 
versions (40) 
Abbreviations: DIELH = Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen; DLQI = Dermatology Life Quality Index; FLQA-c  = Freiburg Life Quality Assessment core 
module; FLQA-d = Freiburg Life Quality Assessment for Dermatoses; ISDL = Impact of Chronic Skin Disease on Daily Life; ND = Not described; QoLIAD = Quality of Life Index for Atopic Dermatitis; 
UK = United Kingdom; US = United States (of America); VAS = visual analogue scale
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Characteristics of the included studies 
Table 5 contains information on the settings and the study populations in the included studies. All 
included studies were conducted in Europe with the exception of the validation studies of the US 
versions of the QoLIAD and the Skindex-29. Most studies recruited their participants in a secondary 
care setting while primary care patients were included in only two studies. Additionally, there was 
significant variation with respect to sample size, with 15 patients being the smallest and 286 patients 
the largest sample size of a single study. 
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Table 5: Important characteristics of the included development and validation studies. 
  Study characteristics 
     Study population 
QoL 
instrument 
Number 
of studies 
Geographic 
location(s) 
Language(s) Setting(s) 
Number of 
participants per 
study 
Age 
range 
(years) 
DIELH 2 (32, 33) Germany German Secondary care 
85 (32) ND 
ND (33) 
ND 
(oldest: 
88) 
Danish DLQI 1 (30) Denmark Danish Secondary care 66 ND 
English DLQI 
(UK) 
3 (28, 29, 
35) 
United 
Kingdom 
English (UK) 
Secondary care 
(28) 
13 (28) ND (28) 
Primary care 
(29) 
56 (29) 
16-53 
(29) 
Community (35) 146 (35) 
20-82 
(35) 
German DLQI 1 (23) Germany German Tertiary care 80 ND 
Spanish DLQI 1 (24) Spain Spanish Secondary care 114 ND 
FLQA-c 1 (21) Germany German Tertiary care 253 17-75 
FLQA-d 1 (23) Germany German Tertiary care 80 ND 
ISDL 1 (27) Netherlands Dutch Secondary care 128 16-77 
Dutch 
QoLIAD 
1 (36) Netherlands Dutch Secondary care 
15 (item 
generation) 
ND 
20 (field testing) ND 
46 (validation) 16-67 
English 
QoLIAD (UK) 
2 (34, 36) 
United 
Kingdom 
English (UK) 
Community (34) 146 (34) 
20-82 
(34) 
Community and 
secondary care 
(36) 
36 (item 
generation) (36) 
ND (36) 
21 (field testing) 
(36) 
ND (36) 
Community (36) 
286 (validation) 
(36) 
16-86 
(36) 
English 
QoLIAD (US) 
1 (36) 
United States 
of America 
English (US) 
ND 
ND (item 
generation) 
ND 
Secondary care 
20 (field testing) ND 
178 (validation) 16-78 
French 
QoLIAD 
1 (36) France French 
ND 
ND (item 
generation) 
ND 
Secondary care 
ND (field 
testing) 
ND 
Community 213 (validation) 18-86 
German 
QoLIAD 
1 (36) Germany German 
ND 
ND (item 
generation) 
ND 
Secondary care 17 (field testing) ND 
Community and 
secondary care 
187 (validation) 17-77 
Italian 
QoLIAD 
1 (36) Italy Italian Secondary care 
14 (item 
generation) ND 
15 (field testing) 
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  Study characteristics 
     Study population 
QoL 
instrument 
Number 
of studies 
Geographic 
location(s) 
Language(s) Setting(s) 
Number of 
participants per 
study 
Age 
range 
(years) 
Spanish 
QoLIAD 
1 (31, 36)
* 
Spain Spanish 
ND (36) ND (36) ND (36) 
Community and 
secondary care 
(36) 
20 (field testing) 
(36) 
ND (36) 
Secondary care 
(31, 36) 
83 (validation) 
(31, 36) 
16-81 
(31, 36) 
English 
Skindex-29 
(US) 
1 (26) 
United States 
of America 
English (US) 
Primary and 
secondary care 
103 ND 
German 
Skindex-29 
1 (22) Germany German Tertiary care 76 ND 
Abbreviations: DIELH = Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen; DLQI = Dermatology Life Quality 
Index; FLQA-c = Freiburg Life Quality Assessment core module; FLQA-d = Freiburg Life Quality Assessment for Dermatoses; ISDL = Impact of 
Chronic Skin Disease on Daily Life; ND = Not described; QoLIAD = Quality of Life Index for Atopic Dermatitis; UK = United Kingdom; US = 
United States (of America) 
*Two articles on the Spanish QoLIAD were included but regarded as one study due to duplicate publication. From de Lucas 2003, only 
validation data not presented in Whalley 2004 was taken into account. 
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Validity of the instruments and recommendations 
The number of studies assessing the different measurement properties of each QoL instrument 
identified is given in table 6. From the 15 included studies, we were able to rate the methodological 
quality of 67 measurement properties. One measurement property (1%) was rated as having 
excellent, 18 (27%) as having good, 31 (46%) as having fair and 17 (25%) as having poor 
methodological quality according to the COSMIN checklist. Our synthesis of the results and level of 
evidence for the properties of each instrument is presented in table 7. There was no instrument for 
which all measurement properties of interest have been examined. As a result, none of the 
instruments complied with all of our pre-specified requirements of truth, discrimination and 
feasibility. Detailed results for every single instrument and study included are available as an online 
appendix to this publication (tables E1-E55).  
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Table 6: Number of studies assessing the measurement properties of QoL instruments for adults with eczema 
Measurement 
property 
DIELH 
Danish 
DLQI 
English 
DLQI 
(UK) 
German 
DLQI 
Spanish 
DLQI 
FLQA-
c 
FLQA-
d 
ISDL 
Dutch 
QoLIAD 
English 
QoLIAD 
(UK) 
English 
QoLIAD 
(US) 
French 
QoLIAD 
German 
QoLIAD 
Italian 
QoLIAD 
Spanish 
QoLIAD 
English 
Skindex-
29 (US) 
German 
Skindex-
29 
Internal 
consistency 
/ / 1 (35) / / / / 
1 
(27) 
1 (36) 2 (34, 36) 1 (36) 1 (36) 1 (36) / 1 (36) / / 
Measurement 
error 
/ / / / / / / / / / / / / / / / / 
Reliability / / / / 1 (24) / / / 1 (36) 1 (36) 1 (36) 1 (36) 1 (36) / 1 (36) / / 
Content validity / / 1 (29) / / / / 
1 
(27) 
1 (36) 1 (36) 1 (36) / 1 (36) 1 (36) 1 (36) / / 
Structural validity 1 (33) / 1 (35) / / / / / / 1 (34) / / / / / / / 
Hypothesis 
testing 
2 (32, 
33) 
1 (30) 
2 (28, 
29) 
1 (23) / 1 (21) 1 (23) 
1 
(27) 
1 (36) 1 (36) 1 (36) 1 (36) 1 (36) / 1 (31, 36) 1 (26) 1 (22) 
Cross-cultural 
validity 
/ / / / / / / / / / / / / / / / / 
Responsiveness / / / / 1 (24) 1 (21) / 
1 
(27) 
/ / / / / / / / / 
Abbreviations: DIELH = Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen; DLQI = Dermatology Life Quality Index; FLQA-c = Freiburg Life Quality Assessment core module; FLQA-d = Freiburg 
Life Quality Assessment for Dermatoses; ISDL = Impact of Chronic Skin Disease on Daily Life; QoLIAD = Quality of Life Index for Atopic Dermatitis; UK = United Kingdom; US = United States (of America) 
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Table 7: Summary of measurement properties of QoL instruments for adults with eczema 
Measurement 
property 
DIELH 
Danish 
DLQI 
English 
DLQI 
(UK) 
German 
DLQI 
Spanish 
DLQI 
FLQA-c 
FLQA-
d 
ISDL 
Dutch 
QoLIAD 
English 
QoLIAD 
(UK) 
English 
QoLIAD 
(US) 
French 
QoLIAD 
German 
QoLIAD 
Italian 
QoLIAD 
Spanish 
QoLIAD 
English 
Skindex-
29 (US) 
German 
Skindex-
29 
Internal 
consistency 
/ / --  / / / / Weak Weak ++ + + + / Weak / / 
Measurement 
error 
/ / / / / / / / / / / / / / / / / 
Reliability / / / / + / / / Weak  ? (limited)  
? 
(limited)  
? 
(limited)  
? 
(limited)  
/ 
? 
(limited)  
/ / 
Content validity / / - / / / / Weak ++ ++ ++ / ++ +++ ++ / / 
Structural 
validity 
? 
(limited)  
/ -- / / / / / / 
? 
(moderate) 
/ / / / / / / 
Hypothesis 
testing 
+ Weak + Weak / 
? 
(limited)  
Weak - - + + + + / + ++ 
? 
(limited)  
Cross-cultural 
validity 
/ / / / / / / / / / / / / / / / / 
Responsiveness / / / / + Weak / Weak / / / / / / / / / 
Recommen-
dation 
D D C D B D D C C B B B B D B D D 
Abbreviations: DIELH = Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen; DLQI = Dermatology Life Quality Index; FLQA-c = Freiburg Life Quality Assessment core module; FLQA-d = Freiburg 
Life Quality Assessment for Dermatoses; ISDL = Impact of Chronic Skin Disease on Daily Life; QoLIAD = Quality of Life Index for Atopic Dermatitis; UK = United Kingdom; US = United States (of America) 
Recommendations are defined as follows: A, QoL measurement instrument meets all requirements and is recommended for use; B, QoL measure meets two or more quality items, but performance in all other required 
quality items is unclear, so that the outcome measure has the potential to be recommended in the future depending on the results of further validation studies; C, QoL measure has low quality in at least one required 
quality criterion (≥1 rating of ‘minus’) and therefore is not recommended to be used any more; D, QoL measure has (almost) not been validated. Its performance in all or most relevant quality items is unclear so that it is 
not recommended to be used until further validation studies clarify its quality. 
+++, ++, +, positive rating indicating adequate measurement property; ? (moderate), ? (limited), intermediate rating indicating intermediate measurement property; -, --, negative rating indicating inadequate 
measurement property (please refer to table 2 for further details); Weak = measurement property was assessed only in studies of poor methodological quality; / = not assessed 
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Internal consistency was good for most language versions of the QoLIAD, with Cronbach’s α ranging 
from 0.88 to 0.94 (36). In a population of 146 eczema patients, the Person Separation Index of the 
DLQI amounted to 0.63, resulting in a negative rating for internal consistency (35). For all other 
instruments, there was either no evidence on internal consistency or only evidence from 
methodologically poor studies. Measurement error was not assessed for any of the included 
instruments. An indeterminate rating was found for most language versions of the QoLIAD in terms 
of reliability. Of the other instruments, reliability information was available for the Spanish DLQI only; 
with an Intraclass Correlation Coefficient (ICC) of 0.77 between the two administrations, this 
instrument showed good reliability (24).  
There was moderate evidence of good content validity for most QoLIAD versions. There was strong 
evidence that the Italian QoLIAD has good content validity. Content validity was found to be limited 
for the UK version of the DLQI in a population of 56 eczema patients; these patients considered the 
DLQI not comprehensive and found some items irrelevant (for instance, items 1 and 9 were not 
considered relevant by any patient in that study) (29). Likewise, structural validity of the UK version 
of the DLQI was found to be poor due to non-uniform differential item functioning (DIF) of items 6 
and 7 with respect to gender and age, respectively. Moreover, 2/10 items showed uniform DIF with 
respect to gender, 3/10 items exhibited uniform DIF with respect to age, and there was disease-
specific DIF for 5/10 items when patients with eczema and psoriasis were compared. Item residual 
statistics were indicative of a misfit to the Rasch model, although item-trait interaction suggested 
that the DLQI fits a Rasch model for eczema patients (35). Structural validity of the UK version of the 
QoLIAD as well as of DIELH is unclear. With data available for 15/17 QoL instruments, hypothesis 
testing (i.e. construct validity) was the measurement property most frequently assessed. Good 
construct validity was found for the DIELH and most QoLIAD versions. Correlations between QoLIAD 
(except Dutch and Italian) and DLQI were moderate to high (r=0.58-0.77) with most values being 
above 0.70. Similar but lower correlations were found between QoLIAD (except Dutch and Italian) 
and the Psychological General Well-Being Schedule (PGWB) (r=0.55-0.79) (36). Good convergent 
validity was also demonstrated for the UK version of the DLQI (29). With the exception of the Dutch 
and the Spanish QoLIAD versions, patients could be clearly discriminated according to perceived 
severity, current flares of symptoms and general health using the QoLIAD (36). The ISDL and the 
Dutch QoLIAD got negative ratings for hypothesis testing. While convergent validity of the Dutch 
QoLIAD was adequate, its discriminative validity was poor and resulted in a negative rating (36). The 
English Skindex-29 (US version) had good discriminative validity (26). For the remaining 
questionnaires, hypothesis testing assessments either led to an indeterminate rating or were 
conducted methodologically poorly.  
Responsiveness in eczema patients was investigated for only 3 questionnaires but only the Spanish 
DLQI was proven responsive (24). 
Values for the minimal important change (MIC) or minimal important difference (MID) were not 
available for any of the included questionnaires. Data on floor and ceiling effects (i.e. ≥15% of 
patients having the lowest/the highest score) were available from one study for the QoLIAD. Only the 
US version of the QoLIAD showed some floor effects with 17.1% and 18.5% of respondents having 
the lowest score for visits 1 and 2, respectively. No floor or ceiling effects were observed for the 
other QoLIAD versions (36). In a sample of 56 eczema patients, the English DLQI (UK) exhibited no 
ceiling effects (29). Likewise, there were no floor or ceiling effects in the 13 eczema patients taking 
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part in the development study of the English DLQI (UK) (28). Completion time for the Spanish QoLIAD 
was found to be 5 minutes or less (36). 
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Discussion 
In this systematic review, the measurement properties of seven different adult eczema QoL 
instruments were evaluated. None of these instruments fulfilled all predefined filter criteria for truth, 
discrimination and feasibility, indicating the need for further validation work. 
Currently, no QoL instrument can be highly recommended. In general, more validation research on 
all QoL questionnaires included in this review would be desirable. The QoLIAD (36) in several 
language versions was placed in category B, meaning that it has the potential to be recommended in 
the future depending on the results of further validation studies. The same is true for the Spanish 
language version of the DLQI (24), although less information is available for this instrument 
compared to the QoLIAD. For the majority of the questionnaires, i.e. DIELH (33), Danish DLQI (30), 
German DLQI (23), FLQA-c (21), FLQA-d (23), Italian QoLIAD (36), English Skindex-29 (US) (26) and 
German Skindex-29 (22), further usage cannot be recommended until more validation data is 
available since the perf rmance of these instruments is largely unclear. Three instruments, the 
English DLQI (UK version) (28), ISDL (27) and Dutch QoLIAD (36), were found to have low adequacy in 
at least one required adequacy criterion and therefore are considered problematic for further use in 
eczema patients.   
The QoLIAD, in several language versions, is a valid and internally consistent QoL instrument applying 
a needs-based model. According to this model, QoL is determined by an individual’s ability and 
capacity to satisfy their needs, with high QoL when most needs and lowest QoL when few or none of 
the needs are met. Consequently, instruments based on this model assess the overall impact of a 
disease and its treatment. This is also reflected by the fact that the QoLIAD is the only instrument 
that does not have any content domains in common with the other instruments. As a result, the 
QoLIAD may not cover some of the aspects that clinicians might consider important in clinical 
practice. Floor or ceiling effects of the 25-item questionnaire were almost not observed and it was 
quickly completed. Although good construct validity was shown for most language versions of the 
QoLIAD, the negative rating for hypothesis testing for the Dutch QoLIAD indicates that the QoLIAD’s 
construct validity should be further examined. Reliability, structural validity and cross-cultural validity 
of the QoLIAD are unclear and should also be further investigated. Measurement error and 
responsiveness of the QoLIAD have not yet been investigated. Moreover, interpretability data (i.e., 
definition and ranges of the QoLIAD that represent mild, moderate and severe QoL impairments in 
eczema) are not available. 
The Spanish DLQI is a 10-item QoL instrument that was shown reliable and responsive in eczema 
patients. The validity of this DLQI version has not yet been tested. Even though plenty of information 
concerning floor and ceiling effects as well as other interpretability data is available for other 
language versions of the DLQI in populations other than eczema, respective data of the Spanish DLQI 
obtained in eczema patients are not available.     
We found the English (UK) version of the DLQI to have poor internal consistency, content and 
structural validity in eczema patients. Thus, the English DLQI (UK version) is not suggested to assess 
QoL in eczema patients. Likewise, the ISDL and the Dutch version of the QoLIAD are not suggested for 
use either because of a lack of construct validity.  
As we included a number of instruments that are dermatology-specific and thus were not specifically 
developed for patients with eczema, content validity of those instruments in eczema patients is of 
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great importance. Dermatology-specific instruments are more likely to miss issues that eczema 
patients consider important simply because they were developed for patients with skin disease in 
general. Whereas good content validity was shown for the QoLIAD, an eczema-specific instrument, 
content validity of the included dermatology-specific instruments in eczema patients was almost not 
investigated. One study found limited content validity of the English DLQI (UK) in eczema patients. 
This finding challenges the applicability of the DLQI to eczema patients and raises the question 
whether other language versions of this instrument may have better content validity. Particularly for 
the Spanish DLQI, shown to be adequately reliable and responsive, a thorough examination of its 
content validity in eczema patients is needed. 
As most data on interpretability were not gathered in eczema samples, only little information on 
interpretability was available for the included instruments. For instance, a MIC of 4 points has been 
proposed for the DLQI, but the corresponding studies did not meet our eligibility criteria (41, 42). 
Banding systems to assign clinical meaning to the scores have been suggested both for the DLQI (43) 
and the Skindex-29 (44-46), but none of these studies was found eligible. Thus, future validation 
studies should also look at interpretability in eczema patients.  
Strengths and limitations of this review 
We registered and published a protocol prior to our systematic review and highlighted differences 
between the protocol and final review. A validated, precise search filter was used to identify all 
possibly eligible articles of any language indexed in PubMed, EMBASE or both (47). Aiming to find the 
best evidence for eczema patients, we used predefined and strict eligibility criteria. We applied the 
COSMIN checklist to rate the study quality and gather information on interpretability and feasibility 
(11-14). At least two reviewers were involved in every step of the review process assure quality. 
Frequent discussions took place within the research team in order to resolve discrepancies. 
A potential limitation of our systematic review is that we only searched PubMed and EMBASE, thus 
possibly missing articles listed elsewhere. However, we were not able to find any further eligible 
articles through a thorough hand search. We were not able to retrieve one eligible article providing 
information on the measurement properties of the Ukrainian versions of the Skindex-16 and the 
DLQI (25).  
Recommendations to researchers, clinicians and decision makers 
This review suggests that currently only the QoLIAD and the DLQI have the potential to be 
recommended for use depending on the results of further validation studies. These validation studies 
should investigate several language versions of the QoLIAD and the DLQI, also including the versions 
that were found inadequate for use in eczema patients in order to possibly confirm the findings of 
previous studies, thus strengthening the evidence base for the recommendations presented in this 
systematic review. The Dutch QoLIAD, the ISDL and the UK version of the DLQI are not suggested for 
use in eczema trials unless future validation studies show – in contrast to the existing evidence – 
adequate measurement properties for these instruments. 
Clinicians and researchers should include a QoL measurement instrument in every future eczema 
trial because QoL is one of the core outcome domains of the proposed COS. As no instrument for 
measuring adult QoL in eczema trials can be highly recommended at the moment, the HOME 
initiative suggests using any QoL instrument that is at least valid, reliable and feasible in eczema 
patients (48). Unfortunately, we found in our review that currently no such instrument is available. 
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An ideal solution to this quandary does not exist. Clinicians and researchers need to balance validity, 
reliability and feasibility. We suggest that researchers should include one of the two instruments 
from category B, i.e. the QoLIAD or the DLQI, in their trials. 
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Figure legends 
Figure 1 
Figure 1: Diagram of article flow during literature search and article screening according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards.  
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Abbreviations and symbols used 
 
+ positive rating 
? indeterminate rating 
- negative rating 
AD = atopic dermatitis; AE = atopic eczema; ANOVA = analysis of variance; COSMIN = COnsensus-
based Standards for the selection of health status Measurement INstruments; DIELH = Deutsches 
Instrument zur Erfassung der Lebensqualität; DIF = Differential item functioning; DLQI = Dermatology 
Life Quality Index; EASI = Eczema Area and Severity Index; GWBI = General Well-Being Index; INVAS = 
Investigator overall assessment of disease severity; QoL = quality of life; MCS = Mental component 
score ; NL = Netherlands; PCS = Physical component score; PGI = Patient-Generated Index; PGWB = 
Psychological General Well-Being Index; PRUVAS = subjective measure of pruritus severity; PTVAS = 
subjective measure of eczema severity; SCORAD = SCORing Atopic Dermatitis; SF-36 = Short form 36; 
TCS = topical corticosteroids; UK = United Kingdom; US = United States of America  
Page 32 of 75Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
 
1. Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH) 
 
Table E1: Structural validity of the DIELH 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(E1) 
Principal components analysis within the single 
diagnostic groups (including AE) performed; questions 
were included if they did not load >0.7 on more than one 
factor 
Not given ? 
Number of AE 
patients 
unknown 
fair 
Conclusion: One study assessed structural validity of the DIELH and indicated unclear structural validity as a QoL instrument for eczema 
 Structural validity of the DIELH as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
Table E2: Discriminative validity of the DIELH 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E2) 
Comparison of the sum scores of different 
diagnostic groups (Kruskal-Wallis test); 
hypothesis: Patients with chronic 
inflammatory dermatoses (like AE) have an 
higher impact on QoL 
Median total score for AE 75.5 
(highest value of all diagnostic 
groups); statistically significant 
(p<0.0001) 
+ 85 AE patients fair 
Conclusion: One study assessed discriminative validity of the DIELH and indicated adequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the DIELH as a measurement of QoL: adequate 
 Quality of evidence: fair  
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2. Dermatology Life Quality Index (DLQI) – Danish version 
 
Table E3: Convergent/divergent validity of the Danish DLQI 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E3) 
Spearman correlation 
coefficients between DLQI 
and 8 dimensions/PCS/MCS of 
the SF-36; Spearman 
correlation coefficients 
between DLQI, PRUVAS, 
PTVAS and INVAS; Wilcoxon 
rank scores between DLQI and 
SCORAD 
The spearman correlation coefficients 
between DLQI and 8 dimensions/PCS/MCS of 
the SF-36 range between -0.54 (General 
health) and -0.11 (Bodily pain); most 
correlations <0.5 
Spearman correlation coefficients for DLQI 
were 0.62 with PRUVAS, 0.81 with PTVAS and 
0.82 with INVAS. 
DLQI was significantly (P < 0.0001) associated 
with objective SCORAD. 
- 
66 patients 
with eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the Danish DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the Danish DLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table E4: Discriminative validity of the Danish DLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E3) 
Discriminative was assessed 
(using Wilcoxon rank scores) 
by seeing how well the QOL 
measures could discriminate 
between groups of 
participants according to 
clinical assessed SCORAD 
Differences in DLQI scores between patients 
with mild and moderate AD (according to 
objective SCORAD) were statistically 
significant (P<0.0001). 
+ 
66 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the Danish DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the Danish DLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
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3. Dermatology Life Quality Index (DLQI) – English version (UK) 
 
Table E5: Internal consistency of the English DLQI (UK) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E4) Person Separation Index (PSI) 
0.63 for eczema patients (considered low by 
the author) 
- 
146 patients 
with eczema 
good 
Conclusion: One study assessed internal consistency of the UK version of the DLQI and indicated inadequate internal consistency as a QoL instrument for 
eczema 
 Internal consistency of the English DLQI (UK) as a measurement of QoL: inadequate 
 Quality of evidence: good 
 
Table E6: Content validity of the English DLQI (UK) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E5) 
Comparison of the 
areas/activities in the DLQI 
and those that were 
mentioned by the patients in 
the PGI; hypothesis: patients 
would include a broader 
range of affected areas in 
their responses to the PGI 
than those included in the 
DLQI 
36 patients (64%) mentioned areas or 
activities not part of the DLQI, 20 patients 
identified only areas included in the DLQI; 
DLQI item 1 not mentioned by any patient 
- 
56 patients 
with eczema 
fair 
Conclusion: One study assessed content validity of the UK version of the DLQI and indicated inadequate content validity as a QoL instrument for eczema 
 Content validity of the English DLQI (UK) as a measurement of QoL: inadequate 
 Quality of evidence: fair 
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Table E7: Structural validity of the English DLQI (UK) 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(E4) 
Examination of overall fit to 
the Rasch model by reference 
to the overall item-trait 
interaction χ²-fit value and via 
Item and Person interaction 
statistics; examination of DIF 
by ANOVA of standardized 
residuals. 
DLQI does not fit a Rasch model for the overall 
sample, but fits a Rasch model for AD patients 
(item-trait interaction = 0.460); item residual 
statistics indicative of model misfit for the AD 
patients; 5/10 items showed DIF for different 
parameters (age and/or gender) in the AD 
sample. 5/10 items showed disease-specific 
DIF in the overall sample. 
A single item (item 4, P=0.048) showed misfit 
to the model. Items 4 (P=0.010) and 7 
(P=0.043) showed uniform DIF by gender, and 
item 6 (P=0.012) exhibited nonuniform DIF by 
gender. Items 2 
(P=0.010), 4 (P=0.020), 7 (P<0.001), and 10 
(P=0.028) showed uniform DIF by age, and 
item 7 (p<0.001) showed 
nonuniform DIF by age. 
- 
292 patients 
(overall 
sample, 146 
psoriasis, 146 
eczema) 
146 patients 
(eczema 
sample) 
good 
Conclusion: One study assessed structural validity of the UK version of the DLQI and indicated inadequate structural validity as a QoL instrument for eczema 
 Structural validity of the English DLQI (UK) as a measurement of QoL: inadequate 
 Quality of evidence: good 
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Table E8: Convergent/divergent validity of the English DLQI (UK) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E5) 
Correlation between DLQI and 
PGI and individual DLQI 
questions were calculated. 
The mean PGI scores of 
those who scored 0 on items 
of the DLQI were compared, 
using a t-test, with the 
scores of those who scored 1-
3 in each item of the DLQI. 
Calculation of correlations 
between the DLQI and the 
costs of eczema; hypothesis: 
patients with poor QoL incur 
high total costs, health service 
costs and personal costs 
Total correlation between DLQI and PGI -0.52 
(p<0.001) --> positive rating; Questions 1-5 of 
the DLQI were correlated with the PGI but 
only question 2 had a correlation of >0.5. 
Questions 6-10 were not statistically 
significant correlated. 
Correlations between DLQI and total costs -
0.34 (p<0.01); correlation between DLQI and 
health service costs -0.47 (p<0.001); no 
correlation with personal costs 
Positive rating because correlation with a QoL 
measure (PGI) is higher than these 
correlations 
+ 
56 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the UK version of the DLQI and indicated adequate convergent validity as QoL instrument for 
eczema 
 Convergent/divergent validity of the English DLQI (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair 
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Table E9: Discriminative validity of the English DLQI (UK) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E6) 
Comparison of DLQI scores 
between patients with atopic 
eczema, pruritus and psoriasis 
with patients with acne, basal 
cell carcinoma and viral warts 
Scores for patients with atopic eczema, 
generalized pruritus and psoriasis were higher 
than for patients with acne, basal cell 
carcinoma and viral warts (P<0.001) 
+ 
13 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the UK version of the DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the English DLQI (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
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4. Dermatology Life Quality Index (DLQI) – German version 
 
Table E10: Discriminative validity of the German DLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E7) 
Discriminative validity: 
Comparison of mean and 
subscale scores between 
patients with psoriasis and 
AD; t-test to determine 
statistical significance 
Differences in mean score statistically 
significant (p<0.01); Differences in all subscale 
scores statistically significant except for 
leisure/sport and relationships 
? 
80 patients 
with eczema  
poor 
Conclusion: One study assessed discriminative validity of the German DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the German DLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
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5. Dermatology Life Quality Index (DLQI) – Spanish version 
 
Table E11: Reliability of the Spanish DLQI 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E8) 
Test retest using Intraclass 
Correlation Coefficient (ICC) 
between two administrations 
ICC between the two administrations was 0.77 
(95% CI) for eczema patients 
+ 
45 patients 
with eczema  
fair 
Conclusion: One study assessed reliability of the Spanish DLQI and indicated adequate reliability as a QoL instrument for eczema 
 Reliability of the Spanish DLQI as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E12: Responsiveness of the Spanish DLQI 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(E8) 
Change in scores over three 
visits after starting TCS 
V1 = 4.53, V2 = 2.80, V3 = 1.64. Change 
between V1 and V3 was statistically significant 
(p=<0.001); change between V1 and V2 not 
statistically significant 
? 
69 patients 
with eczema  
fair 
(E8) 
Sensitivity to change - effect 
size (ES) statistic 
ES for change in overall DLQI score between 
visits 1 and 3 was 0.82. 
+ 
69 patients 
with eczema 
fair 
Conclusion: One study assessed responsiveness of the Spanish DLQI and indicated adequate responsiveness as a QoL instrument for eczema 
 Responsiveness of the Spanish DLQI as a measurement of QoL: adequate 
 Quality of evidence: fair 
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6. Freiburg Life Quality Assessment – core module (FLQA-c) 
 
Table E13: Convergent/divergent validity of the FLQA-c 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E9) 
FLQA scores compared to 
SCORAD severity scores using 
Pearson correlation 
coefficient 
Low and moderate correlations between 
severity score and FLQA scales; between r = 
14 and r = 34 in atopic dermatitis patients 
(p108, 2nd column) 
? 
253 patients 
with eczema  
fair 
Conclusion: One study assessed convergent/divergent validity of the FLQA-c and indicated unclear convergent validity as a QoL instrument for eczema 
 Convergent/divergent validity of the FLQA-c as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
Table E14: Discriminative validity of the FLQA-c 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E9) 
Comparison of scores 
between AD and psoriasis 
patients (ANOVA for 
independent samples) 
Differences between AD and psoriasis patients 
statistically significant (p<0.001) for 5/6 
subscales 
? 
253 patients 
with eczema  
fair 
Conclusion: One study assessed discriminative validity of the FLQA-c and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the FLQA-c as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table E15: Responsiveness of the FLQA-c 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(E9) 
Comparison of patient scores 
after 4 weeks of treatment 
(paired t-test) 
Changes in scores on all subscales statistically 
significant (p<0.001) for AD patients 
+ 
Number of AD 
patients 
unknown 
poor 
Conclusion: One study assessed responsiveness of the FLQA-c, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the FLQA-c as a measurement of QoL: unclear 
 Quality of evidence: poor 
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7. Freiburg Life Quality Assessment for Dermatoses (FLQA-d) 
 
Table E16: Discriminative validity of the FLQA-d 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E7) 
Comparison of subscale 
scores between patients with 
psoriasis and AD; t-test to 
determine statistical 
significance 
Differences in all subscale scores statistically 
significant (p<0.01) except for social life and 
treatment --> 4/6 statistically significant 
different --> indeterminate rating (in contrast 
to DLQI no data on mean scores) 
? 
80 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the FLQA-d, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the FLQA-d as a measurement of QoL: unclear 
 Quality of evidence: poor 
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8. Impact of Chronic Skin Disease on Daily Life (ISDL) 
 
Table E17: Internal consistency of the ISDL 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E10) 
Cronbach's alpha but poorly 
described 
Ranged from 0.64 - 0.93 + 
128 patients 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table E18: Content validity of the ISDL 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E10) 
Items based on literature had 
to be relevant for the 
construct to be measured; 
health professionals and 
patients with chronic skin 
diseases evaluated the initial 
item pool, resulting in 30 
eligible items 
Normal distributions of all items in pilot study ? 
Item 
generation: 
unknown 
 
Pilot study: 65 
psoriasis and 
77 AD patients 
poor 
Conclusion: One study assessed content validity of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table E19: Convergent/divergent validity of the ISDL 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E10) 
Convergent validity of ISDL 
assessed with patients rating 
of disease activity on a 4-point 
Likert scale (extent and 
severity of skin involvement 
of main disease characteristics 
for each body area), DLQI, 
anxiety scale (SCL), depression 
scale (SCL) and neuroticism 
scale (EPQ). Calculated 
Pearson's correlation 
coefficient. 
Too many individual results to list. Moderate 
(0.30-0.50) to relatively high (>0.50) 
correlations in expected directions. More 
correlations <0.5 than above 0.5, see table 3 
in paper. 
- 
128 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the ISDL and indicated inadequate convergent validity as a QoL instrument for eczema 
 Convergent/divergent validity of the ISDL as a measurement of QoL: inadequate 
 Quality of evidence: fair 
 
Table E20: Discriminative validity of the ISDL 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E10) 
Comparison of scores of AD 
and psoriasis patients 
AD patients had significantly higher scores for 
itch (t=3.27, p<0.001), scratch response 
(conscious t=4.95, p<0.001; automatic t=6.40, 
p<0.001) and daily-life impact (t=4.14, 
p<0.001); differences in scores on all other 
subscales not statistically significant 
? 
128 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table E21: Responsiveness of the ISDL 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(E10) 
Effect study of 5-session of 
cognitive behavioural group 
therapy programme where 
patients learn to cope with 
itch and reduce scratching to 
assess sensitivity to change. 
Physical functioning: skin status (t=3.85), itch 
(t=5.07), conscious scratching (t=5.47), 
automatic scratching (t=4.80) - all p<0.001, 
pain (t=3.62, p<0.01), fatigue (t=1.89, p<0.07). 
Daily life impact: t=4.31, p<0.001, helplessness 
(t=2.70, p<0.01), acceptance (t= -3.52, 
p<0.01), perceived benefits (t= -3.59, p<0.01), 
anxiety (t=2.43, p=0.02). No significant 
changes for negative and positive mood, 
stigmatization and social support. So 11/16 
showed some correlation. 
? 
49 patients 
with eczema 
poor 
Conclusion: One study assessed responsiveness of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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9. Quality of Life Index for Atopic Dermatitis (QoLIAD) – Dutch version 
 
Table E22: Internal consistency of the Dutch QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.88 (time 1) and 0.89 (time 2) + 
39 patients 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the Dutch QoLIAD, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Dutch QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table E23: Reliability of the Dutch QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.80 ? 
17 patients 
with eczema 
poor 
Conclusion: One study assessed reliability of the Dutch QoLIAD, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the Dutch QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table E24: Content validity of the Dutch QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Interviews (15 NL, 65 total) to 
explore the effect AD has on 
the patient to generate 
wording for items. Tested for 
cultural applicability across 
countries. Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42. Final version had 
25 items - fit to Rasch model. Local 
dependency between items was minimal - 
minimal item redundancy 
+ 
Item 
generation 
and selection: 
15 patients 
with eczema 
 
Field testing: 
20 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the Dutch QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the Dutch QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: good 
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Table E25: Convergent/divergent validity of the Dutch QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.79 
(time 1) and 0.58 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.63 (time 
1) and 0.47 (time 2). 
+ 
39 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the Dutch QoLIAD and indicated adequate convergent validity as a QoL instrument for eczema 
 Convergent/divergent validity of the Dutch QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E26: Discriminative validity of the Dutch QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Dutch measure was not statistically significant 
for all 3 assessment groups. May be due to 
small sample size in Netherlands. 
- 
39 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the Dutch QoLIAD and indicated inadequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the Dutch QoLIAD as a measurement of QoL: inadequate 
 Quality of evidence: fair 
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10. Quality of Life Index for Atopic Dermatitis (QoLIAD) – English version (UK) 
 
Table E27: Internal consistency of the English QoLIAD (UK) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.91 (time 1) and 0.94 (time 2) + 
269 patients 
with eczema 
fair 
(E12) 
Internal consistency was 
assessed using Person 
Separation Index (PSI) 
The PSI given in table 2 indicate there is a 
good level of internal reliability as they were 
greater than 0.7 (0.91 for initial fit of QoLIAD 
and 0.82 when 2 items removed). 
+ 
146 patients 
with eczema 
good 
Conclusion: Two studies assessed internal consistency of the UK version of the QoLIAD and indicated adequate internal consistency as a QoL instrument for 
eczema 
 Internal consistency of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair to good 
 
Table E28: Reliability of the English QoLIAD (UK) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.86 ? 
269 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the UK version of the QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the English QoLIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table E29: Content validity of the English QoLIAD (UK) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Interviews (36 UK, 65 total) to 
explore the effect AD has on 
the patient to generate 
wording for items. Tested for 
cultural applicability across 
countries. Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items. Final 
version had 25 items - fit to Rasch model. 
Local dependency between items was minimal 
- minimal item redundancy 
+ 
Item 
generation 
and selection: 
36 patients 
with eczema 
 
Field testing: 
21 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the UK version of the QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: good 
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Table E30: Structural validity of the English QoLIAD (UK) 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(E12) 
Examination of overall fit to 
the Rasch model by reference 
to the overall item-trait 
interaction χ²-fit value and via 
Item and Person interaction 
statistics; examination of DIF 
by ANOVA of standardized 
residuals. 
QoLIAD fits the Rasch model (item-trait 
interaction = 0.28), although there is evidence 
for marginal multidimensionality. No clear 
item misfit found. Authors do not refer to DIF 
in the results section (except for disease, but 
not statement whether DIF was uniform or 
non-uniform) 
? 
146 patients 
with eczema 
good 
Conclusion: One study assessed structural validity of the UK version of the QoLIAD and indicated unclear structural validity as a QoL instrument for eczema 
 Structural validity of the English QoLIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: good 
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Table E31: Convergent/divergent validity of the English QoLIAD (UK) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.69 
(time 1) and 0.77 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.55 (time 
1) and 0.55 (time 2). 
+ 
269 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the UK version of the QoLIAD and indicated adequate convergent validity as a QoL instrument 
for eczema 
 Convergent/divergent validity of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
Page 54 of 75Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
25 
 
Table E32: Discriminative validity of the English QoLIAD (UK) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001 for 
severity and general health, p<0.01 for flares) 
+ 
269 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the UK version of the QoLIAD and indicated adequate discriminative validity as a QoL instrument for 
eczema 
 Discriminative validity of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair 
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11. Quality of Life Index for Atopic Dermatitis (QoLIAD) – English version (US) 
 
Table E33: Internal consistency of the English QoLIAD (US) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.93 (time 1) and 0.92 (time 2) + 
170 patients 
with eczema 
fair 
Conclusion: One study assessed internal consistency of the US version of the QoLIAD and indicated adequate internal consistency as a QoL instrument for 
eczema 
 Internal consistency of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E34: Reliability of the English QoLIAD (US) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.90 ? 
170 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the US version of the QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the English QoLIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table E35: Content validity of the English QoLIAD (US) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Tested for cultural 
applicability across countries. 
Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items Final 
version had 25 items - fit to Rasch model. 
Local dependency between items was minimal 
- minimal item redundancy 
+ 
Item 
generation 
and selection: 
not described 
 
Field testing: 
20 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the US version of the QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: good 
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Table E36: Convergent/divergent validity of the English QoLIAD (US) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.74 
(time 1) and 0.75 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.55 (time 
1) and 0.67 (time 2). 
+ 
170 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the US version of the QoLIAD and indicated adequate convergent validity as a QoL instrument 
for eczema 
 Convergent/divergent validity of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
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Table E37: Discriminative validity of the English QoLIAD (US) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001 for 
severity and general health, p<0.01 for flares) 
+ 
170 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the US version of the QoLIAD and indicated adequate discriminative validity as a QoL instrument for 
eczema 
 Convergent validity of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
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12. Quality of Life Index for Atopic Dermatitis (QoLIAD) – French version 
 
Table E38: Internal consistency of the French QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.90 (time 1) and 0.92 (time 2) + 
200 patients 
with eczema 
fair 
Conclusion: One study assessed internal consistency of the French  QoLIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the French QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E39: Reliability of the French QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.89 ? 
200 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the French  QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the French QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table E40: Convergent/divergent validity of the French QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.65 
(time 1) and 0.71 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.63 (time 
1) and 0.66 (time 2). 
+ 
200 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the French  QoLIAD and indicated adequate convergent validity as a QoL instrument for 
eczema 
 Convergent/divergent validity of the French QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
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Table E41: Discriminative validity of the French QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001) 
+ 
200 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the French  QoLIAD and indicated adequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the French QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
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13. Quality of Life Index for Atopic Dermatitis (QoLIAD) – German version 
 
Table E42: Internal consistency of the German QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.91 (time 1) and 0.92 (time 2) + 
178 patients 
with eczema 
fair 
Conclusion: One study assessed internal consistency of the German  QoLIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E43: Reliability of the German QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.86 ? 
178 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the German  QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the German QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table E44: Content validity of the German QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Tested for cultural 
applicability across countries. 
Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items. Final 
version had 25 items - fit to Rasch model. 
Local dependency between items was minimal 
- minimal item redundancy 
+ 
Item 
generation 
and selection: 
not described 
 
Field testing: 
17 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the German  QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: good 
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Table E45: Convergent/divergent validity of the German QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.70 
(time 1) and 0.73 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.64 (time 
1) and 0.68 (time 2). 
+ 
178 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the German  QoLIAD and indicated adequate convergent validity as a QoL instrument for 
eczema 
 Convergent/divergent validity of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
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Table E46: Discriminative validity of the German QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001) 
+ 
178 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the German  QoLIAD and indicated adequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
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14. Quality of Life Index for Atopic Dermatitis (QoLIAD) – Italian version 
 
Table E47: Content validity of the Italian QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Interviews (14 Italy, 65 total) 
to explore the effect AD has 
on the patient to generate 
wording for items. Tested for 
cultural applicability across 
countries. Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items. 
+ 
Item 
generation 
and selection: 
14 patients 
with eczema 
 
Field testing: 
15 patients 
with eczema 
excellent 
Conclusion: One study assessed content validity of the Italian  QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the Italian QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: excellent 
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15. Quality of Life Index for Atopic Dermatitis (QoLIAD) – Spanish version 
 
Table E48: Internal consistency of the Spanish QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.88 (time 1) and 0.90 (time 2) + 
80 patients 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the Spanish  QoLIAD, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Spanish QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table E49: Reliability of the Spanish QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.88 ? 
80 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the Spanish  QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the Spanish QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table E50: Content validity of the Spanish QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Tested for cultural 
applicability across countries. 
Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42. Final version had 
25 items - fit to Rasch model. Local 
dependency between items was minimal - 
minimal item redundancy 
+ 
Item 
generation 
and selection: 
not described 
 
Field testing: 
20 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the Spanish  QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the Spanish QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: good 
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Table E51: Convergent/divergent validity of the Spanish QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.76 
(time 1) and 0.75 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.79 (time 
1) and 0.76 (time 2). 
+ 
80 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the Spanish  QoLIAD and indicated adequate convergent validity as a QoL instrument for 
eczema 
 Convergent/divergent validity of the Spanish QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
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Table E52: Discriminative validity of the Spanish QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Spanish measure was not statistically 
significant for flare. Differences on scores 
between the two other assessment groups 
were statistically significant (p<0.001) 
? 
80 patients 
with eczema 
fair 
(E13) 
Calculated differences in 
scores, compared QoLIAD and 
body parts affected 
(face/hands, face, hands), 
QoLIAD and treatment 
because of the symptoms; 
tested for statistical 
significance using Mann-
Whitney-U and Kruskal-Wallis 
test; no hypotheses 
QoLIAD and body parts: p=0.004 for face 
affected, p=0.114 for face/hands, p=0.052 for 
hands --> QoLIAD could distinguish patients 
whose face was affected 
QoLIAD and treatment: p=0.392 
1/4 statistically significant 
? 
79 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the Spanish QoLIAD and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the Spanish QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
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16. Skindex-29 – English version (US) 
 
Table E53: Convergent/divergent validity of the English Skindex-29 (US) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E14) 
Determination of correlations 
between scores on the 
instrument and physician's 
judgment of severity of the 
skin disease using Pearson's 
correlation coefficients 
Significant correlation with the emotion scale 
(r=0.29, P<0.01); correlations for the two 
other scales not statistically significant 
? 
102 patients 
with eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the English Skindex-29 (US), but due to poor methodological study quality no conclusion can 
be drawn  
 Convergent/divergent validity of the English Skindex-29 (US) as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table E54: Discriminative validity of the English Skindex-29 (US) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E14) 
Comparison of scales scores 
of eczema patients with 
patients with isolated lesions 
(benign growths, 
nonmelanoma skin cancer) 
using the Wilcoxon rank-sum 
test 
Hypothesis: Patients with 
inflammatory dermatoses 
would have higher scale 
scores than patients with 
isolated lesions 
Mean scores of patients with eczema were 
significantly higher than those with benign 
skin lesions or nonmelanoma skin cancer 
(P<0.001) for all 3 subscales 
+ 
102 patients 
with eczema 
good 
Conclusion: One study assessed discriminative validity of the English Skindex-29 (US) and indicated adequate discriminative validity as a QoL instrument for 
eczema 
 Discriminative validity of the English Skindex-29 (US) as a measurement of QoL: adequate 
 Quality of evidence: good 
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17. Skindex-29 – German version 
 
Table E55: Discriminative validity of the German Skindex-29 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E15) 
Pearson correlation 
coefficients for each Skindex-
29 subscale with EASI scores 
Correlation between EASI/Skindex-29: 
functioning 0.73, emotion 0.61, symptoms 
0.72 (all statistically significant) 
? 
13 patients 
with eczema 
poor 
(E15) 
Pearson correlation 
coefficients for each Skindex-
29 subscale with self-ratings 
of skin symptoms, itch and 
sleep disturbance 
Correlation between patient ratings of 
severity and Skindex-29: functioning 0.54-
0.59, emotion 0.35-0.40, symptoms 0.62-0.71 
(all statistically significant) 
? 
63 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the German  Skindex-29 and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the German Skindex-29 as a measurement of QoL: unclear 
 Quality of evidence: fair 
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